BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

Stock Information for Lyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lyra Therapeutics Inc.

BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Diamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX)
Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)
Fusion Fuel Appoints Luisa Ingargiola to Board of Directors
BioCorRx Reports Business Update for the Second Quarter of 2024
BioCorRx Reports Business Update for 2023
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.